Table 5.

Post-hoc analysis of clinical trials on targeted agents in breast cancer: CNS relapse after first-line treatment.

Treatment	Molecular Subgroup	Brain Metastases	CNS Relapse	Time to CNS Relapse
Lapatinib + Capecitabine [96]	HER2+ MBC	Untreated	NR	6 months
Lapatinib−Capecitabine vs. Trastuzumab−Capecitabine [97]	HER2+ MBC	Absent	3% 5%	5.7 months 4.4 months
Neratinib−Paclitaxel vs. Trastuzumab−Paclitaxel [98]	HER2+ MBC	Absent or Stable	8.3% 17.3%	NR NR
Neratinib−Capecitabine vs. Lapatinib−Capecitabine [99]	HER2+ MBC	Absent or Stable	23% 29%	NR NR
Tucatinib combination vs. Placebo combination [101]	HER2+ MBC	Active or Stable	NR, NR	13.8 months vs. 24.9 months
Pertuzumab combination vs. Placebo combination [105]	HER2+ MBC	Absent	13% 13%	15 months 12 months
Trastuzumab emtansine vs. Lapatinib−Capecitabine [106]	HER2+ MBC	Absent	2% 1%	NR NR